Helsinn v. Teva challenges whether inventor's sale of an invention to a third party that must in turn keep the invention secret makes it unpatentable; America Invents Act amended "on-sale" bar provision.
The US Supreme Court is tackling a question that could have a major impact on biopharma patent owners: Does the sale of a secret invention to a third party trigger the on-sale bar to patenting under the America Invents Act?
In its June 25 orders, the Supreme Court granted Helsinn Healthcare SA's (Helsinn Group) petition for certiorari, Helsinn v. Teva Pharmaceuticals USA Inc., which challenges the US Court of Appeals for the Federal Circuit's reading of the America Invents Act (AIA)
A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.
The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.
England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.
